learn about working at legal adviser at sbde . co , legal adviser for mr mohamed kaaki, ceo for oversease business group. join linkedin today for free. see who you know at legal adviser at sbde . co , legal adviser for mr mohamed kaaki, ceo for oversease business group, leverage your professional network, and get hired.
Company profile
Ticker
LEXX
Exchange
Website
CEO
Christopher A. Bunka
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LEXARIA CORP., Lexaria Corp.
SEC CIK
Corporate docs
Subsidiaries
Lexaria CanPharm ULC • PoViva Corp. • Lexaria Hemp Corp. • Lexaria Nicotine LLC • Lexaria CanPharm Holding Corp. • Lexaria Pharmaceutical Corp. • Kelowna Management Services Corp. ...
IRS number
202000871
LEXX stock data
Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
9 Apr 24
8-K
Entry into a Material Definitive Agreement
21 Mar 24
EFFECT
Notice of effectiveness
21 Mar 24
424B3
Prospectus supplement
20 Mar 24
8-K
Departure of Directors or Certain Officers
15 Mar 24
S-1
IPO registration
12 Mar 24
DEF 14A
Definitive proxy
6 Mar 24
8-K
Other Events
1 Mar 24
8-K
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
16 Feb 24
D
$3.60 mm in options, sold $3.60 mm, 2 investors
16 Feb 24
Latest ownership filings
3
Nelson Cabatuan
15 Mar 24
SC 13D/A
Boos Wayne W
14 Feb 24
SC 13G/A
Invenomic Capital Management LP
14 Feb 24
4
Vanessa Carle
1 Nov 23
4
JOHN MARTIN DOCHERTY
30 Oct 23
4
CHRISTOPHER BUNKA
30 Oct 23
SC 13D
Boos Wayne W
18 Sep 23
4
Nicholas W Baxter
25 Jul 23
4
William Edward McKechnie
25 Jul 23
4
ALBERT L REESE JR
25 Jul 23
Financial summary
Quarter (USD) | Nov 23 | Aug 23 | May 23 | Feb 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Aug 23 | Aug 22 | Aug 21 | Aug 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.95 mm | 1.95 mm | 1.95 mm | 1.95 mm | 1.95 mm | 1.95 mm |
Cash burn (monthly) | (no burn) | 214.91 k | 379.71 k | 491.99 k | 393.88 k | 484.80 k |
Cash used (since last report) | n/a | 995.91 k | 1.76 mm | 2.28 mm | 1.83 mm | 2.25 mm |
Cash remaining | n/a | 958.26 k | 194.53 k | -325.76 k | 128.86 k | -292.44 k |
Runway (months of cash) | n/a | 4.5 | 0.5 | -0.7 | 0.3 | -0.6 |
Institutional ownership, Q2 2023
9.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 15 |
Opened positions | 0 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 644.64 mm |
Total shares | 1.18 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Invenomic Capital Management | 766.57 k | $559.83 mm |
L1 Capital Global Opportunities Master Fund | 285.71 k | $1.28 mm |
Geode Capital Management | 48.84 k | $35.31 mm |
Vanguard | 33.33 k | $24.34 mm |
Susquehanna International | 15.43 k | $11.16 mm |
Tower Research Capital | 10.95 k | $7.99 mm |
Renaissance Technologies | 10.70 k | $8.00 k |
1832 Asset Management | 2.69 k | $1.96 mm |
Advisor | 2.04 k | $1.49 mm |
WFC Wells Fargo & Co. | 1.07 k | $782.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Oct 23 | Vanessa Carle | Stock Options Common Shares | Grant | Acquire A | No | No | 1.15 | 12,500 | 14.37 k | 52,567 |
26 Oct 23 | Bunka Christopher | Stock Options Common Shares | Grant | Acquire A | No | No | 1.15 | 30,000 | 34.50 k | 131,001 |
26 Oct 23 | Docherty John Martin | Stock Options Common Shares | Grant | Acquire A | No | No | 1.15 | 30,000 | 34.50 k | 124,668 |
25 Jul 23 | Turkel Catherine C. | Stock Options Common Shares | Grant | Acquire A | No | No | 0.87 | 5,000 | 4.35 k | 10,000 |
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
16 Apr 24
Lexaria Receives Ethics Review Board Approval To Begin New GLP-1 Study, Investigating GLP-1 Drugs And DehydraTECH
16 Apr 24
Lexaria Appoints Nelson Cabatuan As Chief Financial Officer, Effective Immediately
14 Mar 24
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
12 Mar 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Mar 24
Press releases
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
16 Apr 24
Lexaria Awarded New Patents
2 Apr 24
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
14 Mar 24
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
7 Mar 24
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
1 Mar 24